Pilot Trial

Benefits

Evidence quality

Highlighted claims

• In the pilot, 90% of intervention participants reduced their opioid dose by at least 50% before surgery compared with 17% in standard care. — Responsible preoperative opioid use for hip or knee arthroplasty (OpioidHALT): a protocol for a randomised clinical trial of pharmacist-partnered opioid tapering prior to hip or knee arthroplasty
• A pilot RCT with 77 participants tested feasibility and acceptability of the pharmacist-partnered opioid tapering intervention before THA or TKA. — Responsible preoperative opioid use for hip or knee arthroplasty (OpioidHALT): a protocol for a randomised clinical trial of pharmacist-partnered opioid tapering prior to hip or knee arthroplasty
• The pilot showed favourable signals for postoperative physical function and persistent opioid use but was not powered for those secondary outcomes. — Responsible preoperative opioid use for hip or knee arthroplasty (OpioidHALT): a protocol for a randomised clinical trial of pharmacist-partnered opioid tapering prior to hip or knee arthroplasty
• The intervention was acceptable to both participants and clinicians in the pilot. — Responsible preoperative opioid use for hip or knee arthroplasty (OpioidHALT): a protocol for a randomised clinical trial of pharmacist-partnered opioid tapering prior to hip or knee arthroplasty